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Objectives. Therapeutic use of the antimicrobial and anti-inflammatory peptides to 
control microbial infection which is a major cause of pulpal and periapical diseases has 
attracted considerable interest in endodontic fields. GV1001 peptide is derived from 
human telomerase reverse transcriptase (hTERT) and was developed as a cancer vaccine. 
Due to its novel pharmaceutical potential with cell-penetrating ability, as well as anti-
 
inflammatory activity, GV1001 peptide was suggested as a therapeutic agent to control 
pulpal inflammation. The purpose of this study was to evaluate the anti-inflammatory 
effect of GV1001 peptide and its related mechanism in P. gingivalis LPS-induced 
inflammation in human dental pulp cells (hDPCs).  
 
Methods. Dental pulp cells from impacted third molars of human adults were isolated and 
cultivated. CHO/CD14/TLR2 and CHO/CD14/TLR4 were used to analyze which toll-like 
receptor (TLR) was stimulated by extracted LPS from P. gingivalis (1 μg/ml). S. aureus 
LTA (1 μg/ml) and E. coli LPS (100 ng/ml) were used as controls. The ability of 
intracellular penetration of GV1001 peptide was analyzed by confocal microscopy. The 
biocompatibility of the peptide (1-50 µM) was measured by MTT assay. Real-time RT-
PCR was performed to investigate the expression levels of TNF-α and IL-6 from LPS-
stimulated hDPCs. The role of MAP kinase (ERK, p38) signaling pathway on the anti-
inflammatory effect of GV1001 peptide was analyzed by western blot analysis. 
Comparisons between 2 groups were analyzed using Mann-whitney U test (P=0.05). 
 
Results. P. gingivalis LPS induced CD25 expression via TLR2. GV1001 peptide was 
predominantly located in the cytoplasm of hDPCs. The peptide down regulated P. 
gingivalis LPS-induced TNF-α and IL-6 production in hDPCs (P < 0.05) without 
showing significant cytotoxicity. Furthermore, the treatment of GV1001 peptide markedly 
inhibited the phosphorylation of MAP kinases (ERK and p38) in LPS-stimulated hDPCs.  
 
 
Conclusions. GV1001 peptide inhibited TNF-α and IL-6 production through reducing P. 
gingivalis LPS-induced phosphorylation of ERK and p38 MAPK in hDPCs, which 
indicates that the peptide may have anti-inflammatory activity. 
 
                                                                                
Keywords: GV1001 peptide, Human telomerase-derived peptide, Porphyromonas 
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Caries, cracks, fractures and leakage from restorations provide pathways for 
microorganisms and their toxins to enter the pulp. Odontogenic infections are generally 
caused by polymicrobial and dominated by anaerobic bacteria (1). The response of the 
pulpal irritation caused by bacteria is inflammation and eventually pulp necrosis may 
occur. The inflammation can spread to the surrounding alveolar bone and cause periapical 
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pathosis. In this process, bacterial lipopolysaccharides (LPS) play a potential role in 
pulpal inflammation. LPS can induce the expression of pro-inflammatory cytokines and 
chemokines, and elicit the innate immune response in dental pulp cells (DPCs) (2). 
Recognition of pathogens and subsequent initiation of innate inflammatory/immune 
events in the dental pulp appear to result from engagement of pattern recognition 
receptors (PRRs) such as Toll-like receptors (TLRs) expressed by these cells (3). 
Signaling pathways initiated by engagement of TLRs from bacterial components lead 
to enhanced transcription of genes responsible for the expression of cytokines, 
chemokines, adhesion molecules, and other mediators of the inflammatory response 
associated with bacterial infection. Of note, the activation of mitogen-activated protein 
kinases (MAPKs) is important in the production of inflammatory cytokines by LPS 
stimulation (4). The MAPK family includes extracellular-signal-related protein kinase 
(ERK), c-JUN N-terminal kinase/stress-activated protein kinases (JNK/SAP) and p38 
MAPK (5). The MAPK signaling pathway is involved in various kinds of cellular 
processes including differentiation, development, proliferation and survival, as well as 
cell death, depending on cell type and stimulus (6, 7). MAPK signaling is activated by 
LPS stimulation during the induction of local pro-inflammatory response (8-10). 
Telomeres are specialized structures at the ends of chromosomes that have a role in 
protecting the chromosome ends from DNA repair and degradation (11). Telomerase is a 
cellular reverse transcriptase (TERT, telomerase reverse transcriptase) which prevents 
premature telomere attrition and maintains normal length and function (12). Human 
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telomerase reverse transcriptase (hTERT) has become an attractive target for cancer 
vaccines due to it being expressed in 85-90% of human cancer tissues, whereas it is 
almost never expressed in normal tissues (13). GV1001 peptide, which is a peptide 
corresponding to amino acids 611-626 of hTERT (EARPALLTSRLRFIPK), has been 
developed as a vaccine against various cancers and has been reported to have the ability 
to penetrate into various cells, including cancer cell lines and primary blood cells (14). 
GV1001 peptide was found to localize predominantly in the cytoplasm and could 
successfully deliver macromolecules such as proteins, DNA and siRNA into cells (14). 
Because of this novel pharmaceutical potential and cell-penetrating ability, as well as its 
own anti-cancer activity, GV1001 peptide is very promising for use in the medical field.  
Recently, the extra-telomeric functions of hTERT have been suggested regarding anti-
apoptotic, anti-aging, antioxidant and anti-inflammatory effects (15-17). Due to its novel 
pharmaceutical potential with cell-penetrating ability, as well as anti-inflammatory 
activity, GV1001 peptide was suggested as a therapeutic agent to control pulpal 
inflammation. 
The purpose of this study was to evaluate the anti-inflammatory effect of GV1001 
peptide and its related mechanism in P. gingivalis LPS-induced inflammation in human 




2. Materials and Methods 
 
Synthesis of GV1001 peptide 
All of the peptides used in this study were synthesized by the Fmoc (9-
fluorenylmethoxycarbonyl)-based solid-phase method and characterized by Peptron Inc. 
(Dae-jeon, Korea). The purities of all peptides used in this study were greater than 95%, 
as determined by high-performance liquid chromatography. 
 
Cultivation of human dental pulp cells 
This study was approved by the Seoul National University Dental Hospital Institutional 
Review Board. The impacted third molars of human adults were collected from 18- to 22-
year-old patients without systemic diseases after obtaining informed consent. The isolated 
dental pulp was cut into small pieces and digested in a solution of 3 mg/mL type I 
collagenase and 4 mg/mL dispase (Sigma Aldrich, St Louis, MO, USA) for 30–60 min at 
37°C. Subsequently, the solution was filtered through a 70-mm cell strainer 
(Becton/Dickinson, Franklin Lakes, NJ, USA). The single-cell suspensions were seeded 
in 35- or 60-mm culture dishes and maintained in a culture media consisting of α-
minimum essential medium (α-MEM; Invitrogen, Carlsbad, CA, USA) supplemented 
with 15% fetal bovine serum (FBS; Gibco-BRL., Life Technologies Inc, Gaithersburg, 
MD, USA), 0.292 mg/mL glutamine (Invitrogen), 100 units/mL penicillin G, 100 mg/mL 
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streptomycin, and 50 mg/mL ascorbic acid (Sigma Aldrich). The cells were incubated in a 
humidified atmosphere containing 5% CO2 at 37°C and cells between 3 and 4 passages 
were used in the following experiments.  
 
Extraction and verification of LPS from P. gingivalis  
P. gingivalis ATCC 33277 was purchased from the American Type Culture Collection 
(ATCC; Manassas, VA, USA) and cultured with brain heart infusion broth (BHI; BD 
Bioscience, Sparks, MD, USA) supplemented with hemin (1 μg/ml) and vitamin K (0.2 
μg/ml) in anaerobic conditions at 37°C. LPS was extracted from P. gingivalis (10 μg/ml) 
cultured according to the method described by Lee et al. (18). E. coli LPS (O111:B4) was 
purchased from Invivogen (San Diego, CA, USA). To confirm the purity of extracted LPS, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 10% 
polyacrylamide gel) was carried out. The LPS was stained with silver nitrate and 
coomassie blue. E. coli LPS was used as a positive control. 
 
Recognized receptors for P. gingivalis LPS by CHO/CD14/TLR2 
or CHO/CD14/TLR4 
CHO/CD14/TLR2 and CHO/CD14/TLR4 were used to evaluate which TLR was used by 
LPS of P. gingivalis, as described previously (19). These cell lines express a gene 
encoding a membrane CD25 driven by the human E-selectin promoter, which contains 
NF-κB binding sites. The cells were grown in Ham’s F-12 medium (Gibco, Rockville, 
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MD, USA) supplemented with 10% FBS, 1 mg/mL G418 (Calbiochem, La Jolla, CA, 
USA) and 400 U/mL hygromycin B (Calbiochem) at 37°C. When the cells were 80% 
confluent, they were treated with P. gingivalis LPS (1 μg/mL), E. coli O111:B4 LPS (100 
ng/mL) or Staphylococcus aureus LTA (1 μg/mL) (InvivoGen) for 16 h in the presence of 
10% FBS. The cells were then washed with PBS, detached with 2 mM 
ethylenediaminetetra-acetic acid (EDTA) in PBS and incubated with fluorescein 
isothiocyanate (FITC)-conjugated mouse anti-human CD25 at 4°C for 30 min. After 
washing with PBS, CD25 expression in the cells was analyzed by flow cytometry. FITC 
conjugated mouse immunoglobulin G (IgG) was used as a control for non-specific 
binding. 
 
Internalization of GV1001 peptide by confocal microscopy 
hDPCs were seeded and cultivated in 2-chamber glass slides (Nunc, Roskilde, Denmark) 
for 12 h. After washing with PBS, cells were incubated in serum-free OPTI-MEM for an 
hour. FITC-labeled 1, 10 and 50 µM of GV1001 peptides were added to cells and 
incubated for 2 h. The cells were fixed with 4% paraformaldehyde solution for 20 min at 
room temperature. The cells were stained with 0.3 μM of DAPI (4,6-diamidino-2-
phenylindole, Molecular Probes®) 642⁄661 nm (Invitrogen) to visualize nuclei and were 
subjected to confocal microscopy. Co-localization of the peptides and nuclei was assessed 
using an FV1000 lager scanning confocal microscope (Olympus, Tokyo, Japan). 
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Cytotoxicity assay of GV1001 peptide on hDPCs 
To evaluate the cytotoxicity of GV1001 peptide on hDPCs, cells (2ⅹ105 /well) were 
treated with several concentrations of GV1001 peptide (0, 1, 5, 10, and 50 µM/well) for 
48 h. The cells were incubated with 5.7 mol/L of MTT solution for 4 h in a tissue-culture 
incubator. A 200 µL quantity of dimethyl sulfoxide solution was then added to the cell-
culture wells, and the plates were shaken for 10 min at room temperature to dissolve the 
precipitated formazan crystals. The solution was centrifuged for 10 min, and the optical 
density of the supernatant was measured at wavelength of 540 nm using an ELISA plate 
reader (PowerWave X 340; BioTek Instruments, VT, USA). 0.9% NaCl solution was used 
as a negative control. The MTT assay was performed three times. 
 
Investigation of MAP kinase (ERK, p38) by western blot analysis 
After addition of 0.75 µM or 10 µM GV1001 peptide to LPS-treated cells, the samples 
were prepared for electrophoresis and were separated using 10% sodium dodecyl sulfate–
polyacrylamide gel with a previously established buffer system (20). After electrophoresis, 
the proteins were transferred onto a nitrocellulose membrane and blocked by Tris-
buffered saline (TBST, 0.05% Tween-20) containing 5% non-fat dried milk. The 
membranes were then incubated with anti-p-ERK and anti-p-p38 (Cell Signaling 
Technology, Beverly, MA, USA) antibodies and subsequently washed with TBST. 
Antigen–antibody complexes were visualized using an enhanced chemiluminescent 
detection system (West-Zol, Seoul, Korea) by incubating membranes with goat anti-rabbit 
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IgG or goat anti-mouse IgG antibody coupled to horseradish peroxidase (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA), diluted at 1:2000. The blots were stripped 
and reprobed with an anti-β-actin polyclonal antibody to ensure that equal amounts of 
protein were used. 
 
Investigation of Cytokine (IL-6, TNF-α) production by real-time 
RT-PCR 
After treatment with 0.75-20 μg/ml LPS for 2, 4, 6, and 8 h, total RNA was isolated from 
the cells using Trizol reagent (Life Technologies Inc, Gaithersburg, MD, USA) according 
to the manufacturer's suggested protocol, and treated with DNase I (RNasefree, RQ1; 
Promega, Madison, WI, USA). One microgram of total RNA was used as a template to 
create first-strand cDNA with oligo-dT priming using an Omniscript RT kit (Qiagen Inc., 
Valencia, CA, USA). The quantitative real-time RT-PCR analyses were performed using 
an ABI Prism 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) 
with a SYBR Premix Ex Taq II kit (Takara, Otsu, Japan) and 35 cycles of PCR. The 
denaturing, annealing, and extension conditions of each PCR cycle were 95°C for 10 s, 
60°C for 15 s, and 72°C for 10 s, respectively. The relative amount or fold change of the 
target gene was normalized relative to the level of the control (untreated cells). The 
following primer sequences were used in the real-time RT-PCR reactions ; 5′-CGA AAG 
TCA ACT CCA TCT GCC- 3′ and 5′-GGC AAC TGG CTG GAA GTC TCT-3′ for IL-6 
gene ; 5′-CCA GGA GAA AGT CAG CCT CCT-3′ and 5′-TCA TAC CAG GGC TTG 
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AGC TCA-3′ for TNF-α gene ; 5’-GTG GTG GAC CTG ACC TGC-3’ and 5’-TGA GCT 
TGA CAA AGT GGT CG-3’ for GAPDH gene 
 
Antimicrobial susceptibility assay of GV1001 peptide against P. 
gingivalis 
GV1001 peptide was dissolved in phosphate buffered saline (PBS; pH7.2) and incubated 
at 4°C for 12 h to form tertiary structure. Antimicrobial susceptibility test of GV1001 
peptide for P. gingivalis ATCC 33277 was carried out according to the recommendations 
of the Clinical and Laboratory Standards Institute (21). The bacteria were cultured in 
exponential phase and harvested by centrifugation at 4,000 x g for 10 min at 4°C. P. 
gingivalis were washed three times and resuspended with PBS. The number of bacteria 
was counted with Petroff-Hasser counting chamber (Hausser Scientific, Horsham, PA, 
USA) and inoculated into 96-well polystyrene plates (SPL Lifescience, Pocheon, Korea) 
containing 10 μl of PBS with or without various concentration of the peptide over a serial 
two-fold dilution range in PBS. The plates including the bacteria was incubated for 1 h at 
37°C in anaerobic condition, and the oxygen-removed BHI broth including vitamin K and 
hemin was added into each well. The bacteria were incubated for 3 days at 37°C in 






The data are expressed as the mean ± standard deviation (SD) of at least 3 separate 
experiments. Comparisons between 2 groups were analyzed using Mann-whitney U test. 
All analyses were performed by SAS (version 8.02, SAS Institue, Cary, NC, USA). P-










Verification of extracted LPS from P. gingivalis 
The extracted LPS from P. gingivalis was analyzed by gel staining after SDS-PAGE. In 
case of staining with coomassie blue, the gel did not show any band. However, staining 
with silver nitrate exhibited the ladder pattern (Fig. 1). Also, staining the agarose gel with 
ethidium bromide did not show any band. These results indicated that the extracted LPS 
from P. gingivalis was uncontaminated with bacterial proteins or nucleic acids. 
The receptors of extracted LPS from P. gingivalis (1 μg/ml), S. aureus LTA (1 μg/ml) 
and E. coli LPS (100 ng/ml) were analyzed by CD25 expression in CHO/CD14/TLR2 
and CHO/CD14/TLR4 cell lines. CD25 was expressed in CHO/CD14/TLR2 cells by P. 
gingivalis LPS, S. aureus LTA and E. coli LPS with cell distribution of 27.54%, 28.92% 
and 45.87%, respectively. However, CHO/CD14/TLR4 cells were not affected by P. 
gingivalis LPS and S. aureus LTA but CD25 expression was induced by E. coli LPS (Fig. 
2). These results indicated that P. gingivalis LPS and S. aureus LTA are agonists of TLR2, 
and E. coli LPS stimulates both TLR2 and TLR4. For the analysis of the cell distribution, 
non-treated cells as the control group was set 4.92%.  
 
Internalization of GV1001 peptide 
As shown in Fig. 3, GV1001 peptides (1, 10 and 50 µM) labeled with FITC at the C-
terminus (FITC-GV) were observed in the cytoplasm of hDPC which confirms cell 
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penetrating ability of the peptide. 
 
Cytotoxicity of GV1001 peptide in hDPCs 
hDPCs were treated with GV1001 peptide, and cytotoxicity was tested by MTT assay. 
GV1001 peptide did not affect the viability of hDPCs in all concentration tested (1-50 
µM), which showed a pattern similar to that of 0.9% NaCl (P < 0.05) (Fig. 4). 
 
Inflammatory cytokine expression by P. gingivalis LPS 
To examine the effects of extracted LPS on the induction of inflammatory cytokine 
expression in hDPCs, the levels of TNF-α and IL-6 expression were evaluated by real-
time RT-PCR after exposing hDPCs to 1 μg/mL of E. coli LPS and P. gingivalis LPS at 
the concentrations of 1, 5, 10, and 20 μg/mL for 10 h. The results showed that IL-6 was 
profoundly induced in the presence of 1, 5, 10, and 20 μg/mL of P. gingivalis LPS and 1 
μg/mL of E. coli LPS (P < 0.05), whereas TNF-α was significantly induced in the 
presence of 10 and 20 μg/mL of P. gingivalis and 1 μg/mL of E. coli LPS (P < 0.05) (Fig. 
5A). 
To evaluate the effects of LPS on inflammatory cytokine expression in hDPCs over a 
period of time, the levels of TNF-α and IL-6 expression were evaluated by real-time RT-
PCR after exposing hDPCs to 20 μg/mL of P. gingivalis LPS or 1 μg/mL of E. coli LPS 
for 2, 4, 6, or 8 hrs. Up-regulation was found in hDPCs after 4 to 8 h of exposure to 20 
μg/mL of P. gingivalis LPS and 1 μg/mL of E. coli LPS (P < 0.05) (Fig. 5B). The 
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expression of TNF-α and IL-6 in hDPCs were upregulated by the LPS in a time- and 
dose-dependent manner. 
 
Inhibitory effect of GV1001 peptide on induction of TNF-α and 
IL-6 by P. gingivalis LPS 
The levels of TNF-α and IL-6 were measured after LPS stimulation to investigate the 
anti-inflammatory activity of GV1001 peptide by real-time RT-PCR. LPS-stimulated 
TNF-α and IL-6 production was significantly inhibited (P < 0.05) (Fig. 6A and 7A). 
 
Decrease of activated ERK and p38 MAPK by GV1001 peptide 
To investigate whether the anti-inflammatory effect of GV1001 peptide was mediated by 
inhibition of LPS binding on TLR2 or by inhibition of the signaling pathway, signaling 
molecules related with TLR2 were investigated by western blot analysis. As shown in Fig. 
6B and 7B, GV1001 peptide reduced LPS-induced phosphorylation of ERK and p38 
MAPK. 
 
Antimicrobial susceptibility test 
As shown in Fig. 8, P. gingivalis showed antimicrobial susceptibility to GV1001 peptide 





Although endodontically treated teeth can maintain their function for a prolonged period 
of time, there are many advantages to maintaining pulp vitality. In immature permanent 
teeth with incomplete apical and dentinal wall development, reparative dentin formation 
is critical for further development of the teeth. Maintaining the vital pulp also has the 
benefit of reducing the occurrence of apical periodontitis by blocking bacterial infections 
(22). Based on these advantages, it is important to maintain or renew pulp vitality. 
Recently, successful pulp regeneration and revascularization techniques have been 
developed and are gaining popularity.  
P. gingivalis is an obligate anaerobic, gram-negative bacterium and is one of the most 
pathogenic species among black-pigmented gram-negative anaerobes (23); which is 
frequently present in root canal infections and odontogenic abscesses (24). P. gingivalis 
may also play a role in symptomatic infections, such as acute apical abscess (25, 26). 
Furthermore, there is a positive association between P. gingivalis and pain, mechanical 
allodynia, swelling and purulent exudates in root canals (26, 27).  
Pathogens are generally recognized by specific receptors, one of which is the TLR 
family. TLR stimulation initiates host defense mechanisms through the activation of 
several intracellular signaling pathways, including activation of the MAP kinases and NF-
κB proteins (28). Exposure of cells to inflammatory stimuli, including LPS and 
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proinflammatory cytokines, results in phosphorylation of MAPK (9).  
Once the TLR is stimulated by a pathogen-associtated molecular pattern, 
proinflammatory cytokines and chemokines are produced by the odontoblast, resulting in 
recruitment and stimulation of immune effector cells and also direct bacterial killing (29). 
Although these biological responses protect the host against invading pathogens, the 
inflammatory response also leads to host tissue damage. Hence, regulating the production 
of these cytokines is pivotal to protecting host tissue.  
The extra-telomeric functions of hTERT are suggested regarding cellular proliferation, 
stem cell mobilization, anti-apoptotic, anti-aging, and antioxidant effects through 
mitochondrial stabilization, transcriptional regulation (15, 16). If the therapeutic use of 
hTERT could be developed, it could be used in the treatment of pulpal diseases. In this 
study, the potential use of a GV1001 peptide of human origin as a therapeutic agent to 
control pulpal inflammation was suggested.  
The anti-inflammatory effect of GV1001 peptide was achieved by modulating the 
suppression of the activation of ERK and p38 MAPK and the subsequent cytokine 
production induced by P. gingivalis LPS stimulation. P. gingivalis and E. coli LPS 
induced TNF-α and IL-6 expression in hDPC in a time- and dose-dependent manner, 
while GV1001 peptide down-regulated IL-6 and TNF-α. hDPCs expressed TLR2 and up-
regulated phosphorylated ERK and p38 MAPK in response to stimulation by LPS. From 
the similar suppression patterns of the two, it could be assumed that the down regulation 
of inflammatory IL-6 and TNF-α by GV1001 was dependent on p38 MAPK and ERK-
16 
signaling respectively, thus indicating that MAPK signaling was associated with down-
regulation of inflammatory cytokines in dental pulp cells by GV1001 peptide. As shown 
in Fig. 6, low concentration of GV1001 peptide was more efficient in lowering TNF-α 
induced by P. gingivalis LPS compared to the high concentration. One of the possible 
reason is that GV1001 peptide can partially aggregate in the high concentration since the 
cell culture medium does not contain carrier proteins. Thus, GV1001 peptide in low 
concentrations which did not aggregate, penetrate into the cells, and react with signaling 
molecules related to inflammation. 
In another previous study, GV1001 peptide was reported to have the ability to 
penetrate into various cells, including cancer cell lines and primary blood cells, without 
affecting cell viability (14). GV1001 peptide was predominantly located in the cytoplasm 
and was used to successfully deliver macromolecules such as proteins, DNA and siRNA 
into cells (14). These cell-penetrating peptides (CPPs) have become one of the most 
popular and efficient tools for delivering various molecules into the cells owing to the 
fact that they have the ability to enter cells independently of a membrane receptor, and 
they show no cell-type specificity (30). In this study, GV1001 peptide was observed in 
the cytoplasm of hDPCs. This study is significant in that it is the first to demonstrate 
GV1001 peptide as a CPP of human origin to express anti-inflammatory effect of its own, 
without affecting cell viability in hDPCs.  
GV1001 peptide had antimicrobial activity against P. gingivalis at the concentration 
as low as 12 μM and also had the ability to neutralize LPS toxicity by inhibiting 
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activation of signaling molecules thus providing a possibility of applications for 
antimicrobial agent.  
Furthermore, future application for vital pulp therapy can be considered; such as the 
use of GV1001 peptide as a pulp-capping agent on reversibly inflamed pulp or an 
alternative to antibiotics in regeneration therapy. The peptide can also be used as an 
intracellular delivery tool for bioactive molecules as shown in the previous study (14). 
Conjugating growth factors such as TGF-βs and BMPs with GV1001 peptide may 
facilitate induction of hDPCs to differentiate effectively into odontoblast-like cells. 
Moreover, further studies may provide an insight for gene therapy to fuse a 
growth/differentiation factor with GV1001 peptide for application in tissue engineering. 
The results from this study may support further research on GV1001 peptide and its 






GV1001 peptide had the ability to penetrate into the cell. The peptide downregulated P. 
gingivalis LPS-induced TNF-α and IL-6 expression through the inactivation of ERK and 
p38 MAP kinase pathways. These findings provide the insight of how GV1001 peptide 
causes anti-inflammatory activities in LPS-stimulated pulpal inflammation without 
significantly affecting host cell viability. GV1001 peptide also showed a potential of 
antimicrobial property against P. gingivalis. Collectively, GV1001 peptide may have 
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Figure 1. SDS-PAGE of P. gingivalis LPS. The LPS was isolated from P. gingivalis by 
LPS extraction kit. SDS-PAGE (10%, acrylamine) was performed, and the gel was 
stained with silver nitrate. E. coil LPS was used as a standard molecule. Pg LPS: P. 










Figure 2. Biological activity of P. gingivalis LPS. CHO/CD14/TLR2 and 
CHO/CD14/TLR4 cells were evaluated to confirm which TLR was used by P. gingivalis 
LPS. CD25 expression in the cells was analyzed by flow cytometry, and the data and 











Figure 3. Internalization of GV1001 peptide into hDPCs. 1, 10 and 50 µM of GV1001 
peptides labeled with FITC at the C-terminus (FITC-GV) were used to treat hDPCs as 






Figure 4. Effects of GV1001 peptide on viability of hDPSCs. The cells (2ⅹ105 cells/well) 
were treated with the indicated concentrations of GV1001 peptide for 48 h. The cell 
viability was assessed by MTT assay and the surviving cell values were shown as the 
percentage of the control-treated cells (no addition of GV1001 peptide); 0.9% NaCl 






Figure 5. Effects of various doses of LPS and exposure times on the expression of IL-6 
and TNF-α in hDPCs. hDPCs were serum-starved for 24 h and treated with indicated 
concentrations of P. gingivalis LPS (1, 5, 10, and 20 μg/mL) (A), for different times (2, 4, 
6, and 8 h) (B). The levels of IL-6 and TNF-α mRNAs were determined by real-time RT-
PCR. Each value indicates the mean ± SD of three independent experiments.  
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* indicates a significant difference (P < 0.05) relative to non-treated cells as control. 1 





Figure 6. Effects of GV1001 peptide on LPS-induced TNF-α and p-ERK production in 
hDPCs. 0.75, 1.5 and 7.5 µM of GV1001 peptide was added to hDPSCs treated with 1 
μg/mL of E. coli LPS or 20 μg/mL of P. gingivalis LPS for 10 h. Real- time RT-PCR and 
western blot revealed down-regulation of (A) TNF-α and (B) phosphorylated ERK, 
respectively, after exposure of cells incubated with GV1001 peptide and 1 μg/mL of E. 
coli LPS or 20 μg/mL of P. gingivalis LPS. Each value indicates the mean ± SD of three 
independent experiments.  
* indicates a significant difference (P < 0.05) relative to non-treated cells as control. 
# indicates a significant difference (P < 0.05) relative to cells treated with LPS in the 





Figure 7. Effects of GV1001 peptide on LPS-induced IL-6 and p-p38 expression in 
hDPCs.  
0.75, 1.5 and 7.5 µM of GV1001 peptide was added to hDPCs treated with 1 μg/mL of E. 
coli LPS or 20 μg/mL of P. gingivalis LPS for 10 h. Real-time RT-PCR and western blot 
revealed down-regulation of (A) IL-6 and (B) phosphorylated p38, respectively, after 
exposure to 1 μg/mL of E. coli LPS or 20 μg/mL of P. gingivalis LPS incubated with 
GV1001 peptide (0.75, 1.5 µM and 7.5 µM). Each value indicates the mean ± SD of three 
independent experiments.  
* indicates a significant difference (P < 0.05) relative to non-treated cells as control.  
# indicates a significant difference (P < 0.05) relative to cells treated with LPS in the 




Figure 8. Antimicrobial susceptibility test of GV1001 peptide for P. gingivalis was carried 
out according to the recommendations of the Clinical and Laboratory Standards Institute. 





국 초  
 
사람 Telomerase 래 펩타이드가  
Porphyromonas gingivalis Lipopolysaccharide 
에 해 도  사이토카인 에 미치는  
항염증 효과에 한 연구  
 
고  진 
울 학  학원 치 과학과 치과보존학 공 
(지도  손 원 ) 
 
1. 목  
치   치근단 질  주  원인인 균감염  억 하고 조 하  해 항균, 
항염증 펩타이드가 우식  근 치료 역에 소개 고 있다. Human 
telomerase reverse transcriptase (hTERT) 래  항암 신  개  
GV1001 펩타이드는 포내  들어가 약리학  효과를 나타내는 것과 함께, 
항염 효과도 보고 고 있어, 치  염증 질  치료에  용 가능  시하
33 
다. 본 연구  목  사람 치  포에  P. gingivalis  LPS  도  
염증에 한 GV1001 펩타이드  항염 효과를 알아보  함이다. 
 
2. 재료  법 
인  매복 3 구치에  치 포를 분리 양하 다. P. gingivialis LPS 
(1 μg/ml)가 어떠한 Toll-like receptor (TLR)를 자극하는지 인하  하
여 CHO/CD14/TLR2  CHO/CD14/TLR4를 사용하여 검증하 고 S. 
aureus LTA (1 μg/ml)  E. coli LPS (100 ng/ml)는 조군  사용하 다. 
Confocal microscopy  GV1001 펩타이드  포질내 과를 인하 다. 
사람 치 포에 한 GV1001 펩타이드 (1-50 µM)  포독  MTT 
assay  분 하 고, P. gingivalis  LPS   염증 사이토카인인 
TNF-α  IL-6  양  real-time RT-PCR  분 하 다. GV1001 펩
타이드  항염 효과에 MAP kinase (ERK, p38) 신 달 과 이 여하는지
를 western blot 분  인하 다. 만- 트니 U검증  통하여 통계학  
 검증하 다 (P=0.05).  
 
3. 결과 
P. gingivalis LPS는 TLR2를 통해 CD25를 하 다. GV1001 펩타이드가 
사람 치  포내  들어가 포질 내에 분포하 고, 사람 치  포에  
포독  나타내지 않고 P. gingivalis LPS  도  TNF-α  IL-6  생
34 
 하게 감소시 다 (P < 0.05). 한 GV1001 펩타이드는 LPS  자극
 사람 치  포에  MAP kinases (ERK, p38)  인산 를 하게 억
하 다.  
 
4. 결  
GV1001 펩타이드는 사람 치  포에  P. gingivalis LPS  도  ERK  
p38 MAPK  인산  억 를 통해 TNF-α  IL-6   감소시  항염 
효과를 나타내었다.  
 
                                                                                
주요어: GV1001 펩타이드, 사람 telomerase 래 펩타이드, 
Porphyromonas gingivalis LPS, MAP kinase (ERK, p38), 항염 효과 
학 번: 2012-30589 
 
 
 
 
 
 
